Home Merck Announces Canadian Approval of GRASTEK (Standardized Allergenic Extract, Timothy Grass (Phleum pratense) Sublingual Tablet)
 

Keywords :   


Merck Announces Canadian Approval of GRASTEK (Standardized Allergenic Extract, Timothy Grass (Phleum pratense) Sublingual Tablet)

2014-02-03 14:30:00| Merck.com - Product News

Dateline City: WHITEHOUSE STATION, N.J. GRASTEK (Timothy Grass Pollen Allergen Extract) Remains Under FDA Review in the United States WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the regulatory approval and launch of GRASTEK (Timothy grass pollen allergen extract) sublingual tablets in Canada. This represents the first approval of GRASTEK for Merck. The product is currently marketed by ALK-Abello in Europe as GRAZAX. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orRobert Consalvo, 908-423-6595orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: approval canadian grass extract

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
14.11
14.115
14.11MTGfoil
14.11
14.11sw14000XH 8000
14.11katie
14.11EX 330 HP SAR
14.11 M1
More »